Medtronic, Inc. v. Teleflex Life Sciences Ltd.,, No. 22-1721 (Fed. Cir. 2023)
Annotate this CaseTelefex’s 116 patent. is directed to a method for using a guide extension catheter with a guide catheter. In 2019, Medtronic launched its own allegedly infringing guide extension catheter product, Telescope. Medtronic filed two petitions for inter partes review (IPR) of the 116 patent. The Federal Circuit affirmed the Patent and Trademark Office Patent Trial and Appeal Board in holding that Medtronic had not shown the challenged claims to be unpatentable. In finding that the claimed invention was conceived before the critical date of alleged prior art (Itou), the court determined that the claimed invention was actually reduced to practice before the critical date of Itou and the patent owner diligently pursued work on the invention until its constructive reduction to practice. “In vivo” testing was not required for actual reduction to practice because the claims at issue are method claims reciting “advancing . . . a guide catheter . . . through a main blood vessel to an ostium of a coronary artery.”
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.